PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
21.62%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.56%. Joel Greenblatt would investigate if growth quality matches quantity.
-25.74%
Cost reduction while Drug Manufacturers - Specialty & Generic median is 1.13%. Seth Klarman would investigate competitive advantage potential.
39.20%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.02%. Joel Greenblatt would investigate competitive advantages.
14.45%
Margin change of 14.45% versus flat Drug Manufacturers - Specialty & Generic margins. Walter Schloss would verify quality.
38.52%
R&D change of 38.52% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
111.30%
G&A change of 111.30% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
6.88%
Marketing expense change of 6.88% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
17.25%
Other expenses change of 17.25% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
72.86%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.14%. Jim Chanos would check for waste.
49.34%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.25%. Jim Chanos would check for waste.
6.22%
Interest expense change of 6.22% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
94.53%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.65%. Jim Chanos would check for overinvestment.
141.87%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.88%. Joel Greenblatt would investigate advantages.
-128.08%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 4.94%. Seth Klarman would investigate causes.
-255.04%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 8.99%. Seth Klarman would investigate causes.
-191.92%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 7.65%. Seth Klarman would investigate causes.
168.55%
Other expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.82%. Jim Chanos would check for issues.
153.87%
Pre-tax income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 11.49%. Joel Greenblatt would investigate advantages.
108.74%
Pre-tax margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.24%. Joel Greenblatt would investigate advantages.
1281.17%
Tax expense growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.56%. Jim Chanos would check for issues.
102.01%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 16.71%. Joel Greenblatt would investigate advantages.
66.09%
Net margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.95%. Joel Greenblatt would investigate advantages.
60.99%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 15.97%. Joel Greenblatt would investigate advantages.
101.35%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 17.38%. Joel Greenblatt would investigate advantages.
16.05%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.01%. Jim Chanos would check for issues.
14.82%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.01%. Jim Chanos would check for issues.